anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
VNX-101 is an investigational adeno-associated virus (AAV) gene therapy developed to express a secreted anti-CD19/anti-CD3 scFv diabody (termed GP101). GP101 binds both cluster of differentiation (CD)19 and CD3, inducing T-cells to kill both benign and malignant B-cells. Following a single intravenous (IV) infusion, the vector induces the liver and key tissues to continuously secrete GP101 into the bloodstream, resulting in long-term, consistent serum levels of GP101. Potential advantages of VNX-101 over autologous CAR-T therapy include it is off-the-shelf, provides a gentle onset of action, does not require lymphodepletion chemotherapy, engages all T-cells continuously (including those freshly produced from the bone marrow), and utilizes highly efficient signaling through the native T-cell receptor.

In this 2-part study, dose-finding data from Part 1 of the study (n=\~12 patients with marrow blasts \<5%) will be used determine the dose for Part 2 in patients at higher disease burden (marrow blasts \<50%). Part 1 is a dose-finding PK study in adults ≥18 years old designed to determine the minimal dose that achieves target PK serum levels of GP101 at steady state (8-week timepoint) without dose-limited toxicities, defined as the recommended Part 2 dose (RP2D). Prior to VNX-101 dosing, subjects may undergo standard of care chemotherapy to meet dosing criteria. Part 2 (n=\~14) will be opened following data safety monitoring board review of Part 1 data and is designed to determine the safety and pharmacokinetics (PK) of VNX-101 at the RP2D in a broader array of subjects with higher leukemic burden (i.e. bone marrow blasts \<50%). The age range for Part 2 will be expanded to include subjects ≥13 years old. Patients will be followed for safety and efficacy up to 5 years post VNX-101 dosing. Long-term follow-up assessments for safety will be conducted for 6 to 15 years post VNX-101 dosing.
The invention relates to a composition stomach medicine made from alginates. The composition stomach medicine is composed of aluminum alginate and potassium alginate at a random weight ratio. Generally, the composition stomach medicine comprises 5 to 95wt% of aluminum alginate, and the balance potassium alginate. Aluminum alginate in the composition stomach medicine can be replaced by a mixture of alginic acid and aluminium hydroxide dried gel. Adult average body weight is assumed to be 60kg, so that aximum daily dosage of aluminum alginate ranges from 0.6 to 4.5g, and maximum daily dosage of potassium alginate ranges from 0.6 to 3.72g. After consumption of the composition stomach medicine, a layer of gel film is formed on human stomach walls, and is capable of protecting gastric mucosa from stimulation caused by gastric acid. Aluminum alginate can not be absorbed in digestive tract, so that long-term consumption is possible.
Type 2 diabetes mellitus (T2DM) is a chronic inflammatory disease that can compromise the functioning of various organs, including the salivary glands (SG). The purinergic system is one of the most important inflammatory pathways in T2DM condition, and P2X7R and P2X4R are the primary purinergic receptors in SG that regulate inflammatory homeostasis. This study aimed to evaluate P2X7R and P2X4R expression, and morphological changes in the submandibular gland (SMG) in T2DM. Twenty-four 5-week-old mice were randomly assigned to control (CON) and diabetes mellitus (DM) groups (n = 12 each). Body weight, diet, and blood glucose levels were monitored weekly. The histomorphology of the SMG and the expression of the P2X7R, and P2X7R was evaluated by immunohistochemistry (IHC) staining and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) at 11 and 13 weeks of age. Our findings indicate a significant increase in food consumption, body weight, and blood glucose levels in the DM group. Although a significant increase in P2X7R and P2X4R expression was observed in the DM groups, the receptor location remained unchanged. We also observed a significant increase in the acinar area in the DM13w group, and a significant decrease in the ductal area in the DM11w and DM13w groups. Targeting purinergic receptors may offer novel therapeutic methods for diabetic complications.
Methods for expressing a variety of biologically active PDGF analogs in eucaryotic cells are disclosed. The methods generally comprise introducing into a eucaryotic host cell a DNA construct capable of directing the expression and secretion of biologically active PDGF analogs in eucaryotic cells. The DNA construct contains a transcriptional promoter followed downstream by a suitable DNA sequence. The DNA sequence may encode a protein substantially homologous to the A-chain or the B-chain of PDGF, or a portion thereof, or an A-B heterodimer. In addition, a portion of the DNA sequence may encode at least a portion of the A-chain, while another portion encodes at least a portion of the B-chain of PDGF. Eucaryotic cells transformed with these DNA constructs are also disclosed. Methods of promoting the growth of mammalian cells, comprising incubating the cells with a biologically active PDGF analog expressed by a eucaryotic host cell transformed with such a DNA construct, are also disclosed.
Reports of necrotizing fasciitis of the perineum (Fournier's Gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including STEGLATRO. Cases have been reported in females and males. Serious outcomes have included hospitalization, multiple surgeries, and death.

Patients treated with STEGLATRO presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue STEGLATRO, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.
Coronary artery disease (CAD) exists on a spectrum of disease represented by a combination of risk factors and pathogenic processes. An in silico score for CAD built using machine learning and clinical data in electronic health records captures disease progression, severity and underdiagnosis on this spectrum and could enhance genetic discovery efforts for CAD. Here we tested associations of rare and ultrarare coding variants with the in silico score for CAD in the UK Biobank, All of Us Research Program and BioMe Biobank. We identified associations in 17 genes; of these, 14 show at least moderate levels of prior genetic, biological and/or clinical support for CAD. We also observed an excess of ultrarare coding variants in 321 aggregated CAD genes, suggesting more ultrarare variant associations await discovery. These results expand our understanding of the genetic etiology of CAD and illustrate how digital markers can enhance genetic association investigations for complex diseases.
In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue.
The exercise group will perform stretching and strengthening exercises involving the muscle groups around the shoulder and scapula for 12 weeks. In addition to the exercises, thoracic mobilization will be applied to the participants in this group 1 day a week for a total of 6 weeks.
The PRP procedure with the same characteristics will be used in the treatment of patients in the PRP group. The PRP application will be prepared by the orthopedics and traumatology specialist physician in the research team, using the kits provided within the scope of the project. In order to collect venous blood for the PRP production procedure, gamma sterile vacuum tubes and blood collection set in special kits without the risk of contamination will be used. A total of 3 doses will be administered to the patients, with a one-week interval between doses.
Participants randomized to the treatment group will receive nine (9) shockwave sessions in total: one (1) shockwave session once per week for four (4) weeks, followed by one (1) shockwave session once per month (30±7 days) for the next five (5) months. 1,440 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura) for a total of 12,960 shocks. Participants will be in this group for up to 6 months.
The invention discloses a novel instant, edible and pharmaceutical composition of Chinese date and manyflower solomonseal rhizome and a preparation process thereof. The novel instant, edible and pharmaceutical composition of Chinese date and manyflower solomonseal rhizome is prepared from the following raw materials in parts by weight: 10 to 30 parts of Chinese date and 10 to 15 parts of manyflower solomonseal rhizome. The preparation process comprises the following steps of: weighing the Chinese date and the manyflower solomonseal rhizome according to the calculated dosage; placing the raw materials into a glass beaker; adding water into the glass beaker until the water level is higher than the medicine surface by 2 to 3cm; soaking for 30 minutes for making medicinal materials sufficiently soaked; heating the glass beaker at a temperature of 200 DEG C by using an induction cooker until boiling, then regulating the temperature to 100 DEG C, and keeping a micro boiling state; after boiling, starting to time for 50 minutes until the volume of the obtained product in the glass beaker reaches the required milliliter quantity; and cooling the obtained product and placing the obtained product in a refrigerator for later use. The composition of Chinese date and manyflower solomonseal rhizome, which is disclosed by the invention, has effects of resisting hypoxia, resisting fatigue, improving hemoglobin content and oxidation resistance and improving the cell membrane repair function. A formula and an extraction and preparation method are simple, convenient and easy to operate. An obtained preparation has good stability and easily controlled dosage and can be suitable for improving athletic ability, being applied to clinical rehabilitation and increasing the physical strength.
NEW MATERIAL:3-Hydroxydihydrofusarbin expressed by the formula. USE:Useful as an antimicrobial agent or antitumor agent and a synthetic raw material therefor. PREPARATION:A microorganism, belonging to the genus Fusarium and capable of producing 5-hydroxydihydrofusarbin is aerobically cultivated to afford the aimed compound expressed by the formula. Fusarium solani f. sp. pisi T-127 (FERM-P No. 8478) is suitably used as the microorganism capable of producing the 5-hydroxydihydrofusarbin. If a culture medium is suitable for growth of molds and capable of producing the 5-hydroxydihydrofusarbin, it may be used without any particular limitation. After completing the cultivation, the aimed compound is obtained, e.g. by removing microbial cells from the culture by centrifugal separation, etc., extracting the resultant filtrate with a suitable organic solvent, etc., and purifying the extract by adsorption chromatography.
The sea cucumber is largely consumed as a putative functional food. Contains many biologically active substances, but little research on its properties, in vivo, have been made. The present disclosure is related to different diets comprising Isostichopus badionotus, a sea cucumber that grows in southeastern Mexico and the method of preparation of the same. Such diets help decrease the body lipid profile. The wall of the sea cucumber body is cooked (100°C, 1h in water) and lyophilized or dried in oven (70°C for 12 h). Then ground and incorporated in diets containing cholesterol. Diets with I. badionotus improve the lipid profile. Particularly, serum cholesterol, low density lipoproteins, triglycerides and atherogenic index values are greatly reduced by I. badionotus contained in the diets described in the present invention. Total lipids in the liver, triglycerides and cholesterol are also reduced. Boiling or performing a heat treatment of food containing sea cucumber, reduces but does not eliminate its lipid-lowering power. The gene expression of several key genes involved in the cholesterol metabolism of lipids in the liver showed that diets containing I. badionotus repress the induction of key genes related with the exerted dyslipidemia by administering cholesterol supplements. The I. badionotus consumption is beneficial for dyslipidemia although the biological effect is clearly dependent of the preparation method of the l. badionotus, as it is described in the present invention.
Late-stage lung cancer patients (n = 318) meeting the inclusion criteria will be recruited and randomized into one of three groups: 1) Tai-Chi group, 2) aerobic exercise group, or 3) self-management control group. Both the Tai-Chi and aerobic exercise groups will attend twice-weekly group classes for 16 weeks (32 total contact hours). The self-management control group will receive written information regarding the recommended level of physical activity. To evaluate the effectiveness of Tai-Chi and aerobic exercise in alleviating the emotional symptom cluster (primary outcome) and individual symptoms (sleep disturbance, anxiety, depression, fatigue), outcome measures will be conducted at baseline, 8 weeks (mid-point assessment), 16 weeks (post-intervention), and 28 weeks (12-weeks post-intervention). A linear mixed-effects model will be used to study the between-group differences in outcomes. In addition, emotion regulation, mindfulness, and cardiorespiratory fitness will be evaluated at each data collection point, and structural equation modeling will be used for subsequent mediation analysis to determine their mediating role in outcome changes. Qualitative interviews will be conducted to understand patients' experience and evaluation of the interventions.
INTRODUCTION: The impact of mRNA-based coronavirus disease-2019 (COVID-19) vaccines on atrial arrhythmias (AA) and ventricular arrhythmias incidence is unknown.
METHODS: BIOTRONIK Home Monitoring data and Medicare Claims data were utilized to identify individuals implanted with a cardiac implantable electronic device (CIED) between 2010 and 2020 who received one or more doses of COVID-19 vaccine in 2021. The burden of AA (%) in the 3 months postvaccination was compared to those noted in the preceding 3 months using the Wilcoxon signed rank test. Sub-analyses comparing the effects of the influenza vaccine against the COVID-19 vaccine were also evaluated for individuals who received the influenza vaccine in 2020. A 1:1 propensity score match comparison between COVID-19 vaccine and non-vaccinated patients was also performed.
RESULTS: First and second doses of the COVID-19 vaccine were administered to 7757 and 6579 individuals with a CIED (age 76.2 ± 9.0 years, 49% males), respectively. While a small but statistically significant increase in the burden of AA was noted in the 3 months postvaccination compared to the preceding 3 months after the first dose of the COVID-19 vaccine (0.43 ± 9.04%, p = .028) a similar rise in AA was found following the influenza vaccine and for matched patients who did not receive the COVID-19 vaccine. No significant difference in device therapies was seen pre- and postvaccination.
CONCLUSIONS: Though we report a small but significant increase in the number of CIED-detected AAs following vaccination for COVID-19 over a 3-month window, we believe these results correlate more with time and the progressive nature of AF rather than the vaccine itself. While these data should not dissuade from the use of these vaccines, increased vigilance and prompt treatment of AF is required for high-risk groups, specifically males over 70 years of age, following vaccination.
Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
FIELD: chemical-pharmaceutical industry, phytotherapy. SUBSTANCE: walnut ground fruits, pericarps and leaves with flower pollen and propolis are used as vegetable raw. The latter is extracted with aviation kerosene taken in the ratio 1:1 for two stages. Process is carried out at temperature 20-30 C for 15-25 days in the first stage and for 25-35 days in the second stage. EFFECT: increased content of biologically valuable components in extract. 1 ex
The invention relates to an attenuated  Salmonella  sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated  Salmonella  sp. to a patient having a solid tumor cancer, wherein said attenuated  Salmonella  sp. is a tumor targeting attenuated  Salmonella  sp. expressing a short hairpin (sh) RNA which attenuated  Salmonella  sp. is capable of inhibiting the growth or reducing the volume of the solid tumor cancer when administered in vivo.
Eligible participants will continue to receive upadacitinib or placebo for 68 weeks. Participants will be followed-up for approximately 30 days.
INTRODUCTION: The use of valproic acid (VPA) in the treatment of some psychiatric and neurological disorders such as bipolar disorder, migraines, and epilepsy is associated with hyperammonemia. However, the mechanism of this negative effect of VPA is unclear. In this study, we investigate gene glutamate-ammonia ligase (GLUL) polymorphisms for the glutamine synthetase (GS) enzyme, a key enzyme that catalyzes the removal of ammonia by incorporating it with glutamate to form glutamine, and we investigate whether it has a relationship with the emergence of hyperammonemia during VPA-based therapy.
PATIENTS AND METHODS: We enrolled 180 Egyptian epilepsy patients in this study. Patient history, general and neurological examination and blood samples from arm veins were taken. Real time TaqMan PCR polymorphism for three polymorphism SNPs (rs2296521, rs10911021 and rs12136955) of GLUL was done. We assessed the relationship between the patient features, including three GLUL polymorphisms, and the development of hyperammonemia during VPA-based therapy.
RESULTS: We found that the ammonia levels showed a positive correlation with VPA treatment duration (p = 0.015) and a negative correlation with carbamazepine total dose per day (p = 0.027) and with WBCs count (p = 0.026). Also, female patients having rs2296521 SNPs with the A allele and patients having rs10911021 SNPs with the C allele were at high risk for elevated plasma ammonia levels. Moreover, patients having rs12136955 SNPs with the A allele or associated hypertension as a co-morbidity were at high risk for elevated plasma ammonia levels.
CONCLUSION: Female patients who have rs2296521 with the A allele, rs10911021 with the C allele, or rs12136955 with the A allele, are independent risk factors for elevated plasma ammonia levels during VPA-based therapy. Moreover, carbamazepine combined therapy may protect against the development of hyperammonemia in VPA-treated patients.
BACKGROUND: Modifying the autonomic system after catheter ablation may prevent the recurrence of atrial fibrillation (AF). Evaluation of skin sympathetic nerve activity (SKNA) is a noninvasive method for the assessment of sympathetic activity. However, there are few studies on the effects of different energy settings on SKNA.
OBJECTIVE: To investigate the changes in SKNA in different energy settings and their relationship to AF ablation outcomes.
METHODS: Seventy-two patients with paroxysmal and persistent AF were enrolled. Forty-three patients received AF ablation with the conventional (ConV) energy setting (low power for long duration), and 29 patients using a high-power, short-duration (HPSD) strategy. The SKNA was acquired from the right arm 1 day before and after the radiofrequency ablation. We analyzed the SKNA and ablation outcomes in the different energy settings.
RESULTS: Both groups had a similar baseline average SKNA (aSKNA). We found that the median aSKNA increased significantly from 446.82 μV to 805.93 μV (p = 0.003) in the ConV group but not in the HPSD group. In the ConV group, patients without AF recurrence had higher aSKNA values. However, the 1-year AF recurrence rate remained similar between both groups (35 % vs. 28 %, p = 0.52).
CONCLUSION: The post-ablation aSKNA levels increased significantly in the ConV group but did not change significantly in the HPSD group, which may reflect different neuromodulatory effects. However, the one-year AF recurrence rates were similar for both groups. These results demonstrate that the HPSD strategy has durable lesion creation but less lesion depth, which may reduce collateral damage.
Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
FIELD: biochemistry, more particularly preparation of concentrate of coagulating proteins from whole human or animal plasma used as biological adhesive. SUBSTANCE: concentrated proteins comprise predominantly fibrinogen stabilizing fibrin factor (factor XIII) and fibronectin. Method does not take much time to accomplish, does not require addition of protease inhibitor, gives excellent yield of proteins to be coagulated, involves stags of separation by "salting out" in the presence of amine-6- hexanic acid which prevents co-precipitation of plasminogen with desired proteins to by coagulated. The resulting proteins are very stable after reconstituting in water for at least 24 hours at room temperature or at body temperature. After being mixed with thrombin and calcium, this biological adhesive shows superior adhesive strength and biocompatibility. EFFECT: more efficient preparation method. 15 cl, 2 ex